Public welfare cooperation breaks through the inclusive closed loop, CH BIOTECH SER (08037) commercialization of BNCT again welcomes key catalysis.

On July 13th, at the Huada Timespace Center in Shenzhen, Huada Group CEO Yin Ye, CH BIOTECH SER (08037) Chairman of the Board Liu Xiaolin, and Deputy Director of the Boao Lecheng International Medical Tourism Pilot Zone Management Bureau in Hainan, Liao Jingle, jointly launched the "BNCT Tumor Patients New Life Support Plan". With a special fund of 5 million yuan, 50 assistance slots, and a maximum treatment subsidy of 10,000 yuan per person, the program is targeted towards connecting with BNCT treatment at the Pengbo (Hainan) Boron Neutron Medical Hospital. This industry collaboration spanning medical, technology, and public welfare sectors not only provides a lifeline of hope for families facing cancer, but also fills a crucial missing piece in the commercialization loop for CH BIOTECH SER's BNCT. Breaking through public welfare: From "technology accessibility" to "payment accessibility" BNCT is hailed as the "jewel on the crown of radiotherapy" due to its unique advantages of non-invasive irradiation for about 30 minutes per session and low damage to normal tissues, making it the optimal solution for difficult-to-treat tumors such as recurrent head and neck cancer and brain glioma. However, the treatment cost in the tens of thousands of yuan discourages many low to middle-income patients - the structural contradiction of "top-notch effectiveness but limited accessibility" persists as the technology is implemented. The assistance plan sets up a multi-faceted assistance model of "government guidance + corporate support + foundation operation + hospital implementation" to address the industry pain points. Liu Xiaolin stated, "Pengbo, Huada Group, and the Mammoth Foundation are deeply collaborating this time, hoping to create a closed-loop ecosystem from 'precision screening' to 'precision treatment' to 'economic inclusivity'. Behind the solid numbers is not only the reduction of medical expenses, but also a beacon of hope for families on the brink." Insurance + public welfare + credit: Formation of a multi-level payment system This partnership is not just an isolated charity effort, but a deep grounding of industry synergy between CH BIOTECH SER and Huada. With the introduction of 30 million yuan financing from Huada's Songhe in 2024 and a 35 million USD convertible bond from Mr. Gong Hongjia in 2025, the two sides have extended from capital collaboration to business collaboration. In early 2026, Pengbo Hospital and Huada Cells reached a strategic cooperation to explore joint genetic testing, cell therapy, and BNCT treatment plans. Now extending to public welfare assistance, the full chain of early cancer screening, BNCT treatment, and subsidies for expenses has been fully connected. Of note, in addition to the public welfare subsidy in this program, the company has previously launched a BNCT exclusive commercial insurance "Boron Companion" and collaborated with banks to provide unsecured installment services for patients. With multiple commercial insurance companies deepening their cooperation with hospitals and exploring including BNCT in their coverage scope, a multi-level payment system of "insurance + public welfare + credit" is taking shape. Leveraging his deep understanding and recognition of boron neutron capture therapy, Huada Group CEO Yin Ye continues to advocate for BNCT using his public influence and professional credibility in the life sciences field, building a strong promotional force of "technology + communication". Double realization of social responsibility and business value From a business perspective, public welfare projects have a strong positive empowerment effect. On one hand, continuous special assistance accumulates real-world clinical cases, laying a solid data foundation for subsequent domestic registration application of BNCT equipment, boron drugs, and clinical research of new indications; on the other hand, green channels and subsidy policies lower the payment threshold for patients, combined with insurance and credit tools, effectively releasing the huge demand of existing head and neck cancer patients. Pengbo (Hainan) Boron Neutron Hospital is currently the only medical institution in mainland China approved to carry out clinical BNCT treatment. Leveraging the "trial first" policy of Boao Lecheng, it has completed a complete loop from technology introduction, equipment procurement, hospital construction to clinical treatment. The entire process from BNCT patient admission to treatment completion takes less than two days, which is not only a breakthrough in medical technology, but also a successful example of China's medical innovation policy and capital synergy. This public assistance program marks the completion of a full chain of technology, clinical, payment, and public welfare for CH BIOTECH SER, effectively improving the accessibility of BNCT, an advanced therapy, not only fulfilling the social responsibility of a medical enterprise, but also continuously magnifying its early-mover advantage in the BNCT field. The integration of cross-institutional resources and full-chain collaborative capabilities also demonstrates the strategic execution power of the organization under ESG governance structure. As cutting-edge cancer treatment technologies truly enter ordinary households, the company is not only witnessing the rebirth of patients, but also a revaluation of its capital market value. As of July 14th, the company's market value was less than 700 million Hong Kong dollars. Compared to its monopoly status and the potential market of the hundred-billion-level BNCT industry, there is a significant room for valuation correction.